Lyme Disease Vaccines Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
LYMErix was introduced in the US as a vaccine against Lyme disease.
Lyme disease (LD) is a tick borne disease caused by infection with the
spirochete, Borrelia burgdorfefi, which manifests itself with rashes, arthritis,
cardiac and neurological disorders. This first vaccine against LD was critical as
the spirochete has an incomplete response to antibiotic treatment. The vaccine
is based on a lipidated outer-surface protein (L-OspA) of the spirochete, which is
prepared by expressing the protein with a post-translational addition at the N-terminal
of the lipid moiety in E. coil strain. After injection of the vaccines,
patients develop antibodies to OspA which either inhibit the growth of the
spirochete or are bactericidal, facilitate phagocytosis and block the attachment
of the organism to host cells. Antibodies produced against this vaccine are
cross-reactive for European and North American strains but not for Japanese
strains. A phase III trial involving 11,000 people in the US showed an overall
vaccine efficacy after three injections of 76% against definite Lyme disease and
100% against asymptomatic infection. LYMErix was generally well tolerated.
Originator
Yale university (US)
Trademarks
LYMErix
Lyme Disease Vaccines Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
